Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 20;48(2):e20210307.
doi: 10.36416/1806-3756/e20210307. eCollection 2022.

Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?

[Article in English, Portuguese]
Mariana Zorron  1 , Fernando Augusto Lima Marson  2 , André Moreno Morcillo  1 , Aline Cristina Gonçalves  1 , Mayra de Souza El Beck  1 , José Dirceu Ribeiro  1 , Antonio Fernando Ribeiro  1
Affiliations

Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?

[Article in English, Portuguese]
Mariana Zorron et al. J Bras Pneumol. .

Abstract
in English, Portuguese

Objective: To determine whether abnormal continuous glucose monitoring (CGM) readings (hypoglycemia/hyperglycemia) can predict the onset of cystic fibrosis-related diabetes (CFRD) and/or clinical impairment (decline in BMI and/or FEV1) in pediatric patients with cystic fibrosis (CF).

Methods: This was a longitudinal prospective cohort study involving CF patients without diabetes at baseline. The mean follow-up period was 3.1 years. The patients underwent 3-day CGM, performed oral glucose tolerance test (OGTT), and had FEV1 and BMI determined at baseline. OGTT, FEV1, and BMI were reassessed at the end of the follow-up period.

Results: Thirty-nine CF patients (10-19 years of age) had valid CGM readings at baseline, and 34 completed the follow-up period (mean = 3.1 ± 0.5 years). None of the study variables predicted progression to CFRD or were associated with hypoglycemic events. CGM could detect glucose abnormalities not revealed by OGTT. Patients with glucose levels ≥ 140 mg/dL, as compared with those with lower levels, on CGM showed lower BMI values and z-scores at baseline-17.30 ± 3.91 kg/m2 vs. 19.42 ± 2.07 kg/m2; p = 0.043; and -1.55 ± 1.68 vs. -0.17 ± 0.88; p = 0.02, respectively-and at the end of follow-up-17.88 ± 3.63 kg/m2 vs. 19.95 ± 2.56 kg/m2; p = 0.039; and -1.65 ± 1.55 vs. -0.42 ± 1.08; p = 0.039. When comparing patients with and without CFRD, the former were found to have worse FEV1 (in % of predicted)-22.67 ± 5.03 vs. 59.58 ± 28.92; p = 0.041-and a greater decline in FEV1 (-36.00 ± 23.52 vs. -8.13 ± 17.18; p = 0.041) at the end of follow-up.

Conclusions: CGM was able to identify glucose abnormalities not detected by OGTT that were related to early-stage decreases in BMI. CGM was ineffective in predicting the onset of diabetes in this CF population. Different diagnostic criteria for diabetes may be required for individuals with CF.

Objetivo:: Verificar se leituras de continuous glucose monitoring (CGM, monitoramento contínuo da glicose) anormais (hipoglicemia/hiperglicemia) podem prever o aparecimento de diabetes relacionado à fibrose cística (DRFC) e/ou comprometimento clínico (declínio do IMC e/ou do VEF1) em pacientes pediátricos com fibrose cística (FC).

Métodos:: Estudo de coorte longitudinal prospectivo envolvendo pacientes com FC sem diabetes no início do estudo. O tempo médio de acompanhamento foi de 3,1 anos. Os pacientes foram submetidos a CGM de três dias, teste oral de tolerância à glicose (TOTG) e medida de VEF1 e IMC no início do estudo. TOTG, VEF1 e IMC foram reavaliados ao final do acompanhamento.

Resultados:: Trinta e nove pacientes com FC (10-19 anos de idade) apresentaram leituras de CGM válidas no início do estudo, e 34 completaram o acompanhamento (média = 3,1 ± 0,5 anos). Nenhuma das variáveis estudadas previu evolução para DRFC ou apresentou associação com eventos hipoglicêmicos. O CGM conseguiu detectar anormalidades glicêmicas não reveladas pelo TOTG. Pacientes com níveis de glicose ≥ 140 mg/dL no CGM, comparados àqueles com níveis menores, apresentaram valores de IMC e escores z de IMC menores no início do estudo - 17,30 ± 3,91 kg/m2 vs. 19,42 ± 2,07 kg/m2; p = 0,043; e −1,55 ± 1,68 vs. −0,17 ± 0,88; p = 0,02, respectivamente - e no final do acompanhamento - 17,88 ± 3,63 kg/m2 vs. 19,95 ± 2,56 kg/m2; p = 0,039; e −1,65 ± 1,55 vs. −0,42 ± 1,08; p = 0,039. Na comparação dos pacientes com e sem DRFC, os primeiros apresentaram pior VEF1 (em % do previsto) - 22,67 ± 5,03 vs. 59,58 ± 28,92; p = 0,041 - e maior declínio do VEF1 (−36,00 ± 23,52 vs. −8,13 ± 17,18; p = 0,041) no final do acompanhamento.

Conclusões:: O CGM foi capaz de identificar anormalidades glicêmicas não detectadas pelo TOTG que se relacionaram com reduções precoces do IMC. O CGM foi ineficaz na previsão do aparecimento de diabetes nesta população com FC. Diferentes critérios diagnósticos para diabetes podem ser necessários para indivíduos com FC.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: None declared.

Figures

Figure 1
Figure 1. Flow chart of patient selection process. CFRD: cystic fibrosis-related diabetes; and CGM: continuous glucose monitoring.
Figure 2
Figure 2. Relationship of oral glucose tolerance test (OGTT) at baseline (T0) and at the end of the follow-up period (T1) with continuous glucose monitoring (CGM) at T0 using OGTT cutoff values in accordance with the American Diabetes Association criteria-normal glucose tolerance (NGT): interstitial glucose < 140 mg/dL; impaired glucose tolerance (IGT): interstitial glucose between 140 and 199 mg/dL; cystic fibrosis-related diabetes (CFRD): interstitial glucose ≥ 200 mg/dL at least twice.
See this image and copyright information in PMC

Comment in

References

    1. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes a technical review. Diabetes Care. 2010;33(12):2677–2683. doi: 10.2337/dc10-1279. - DOI - PMC - PubMed
    1. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151(9):684–687. doi: 10.1007/BF01957574. - DOI - PubMed
    1. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Pt 1Am J Respir Crit Care Med. 2000;162(3):891–895. doi: 10.1164/ajrccm.162.3.9904075. - DOI - PubMed
    1. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. ISPAD Clinical Practice Consensus. Guidelines. 2018:Management–Management. doi: 10.1111/pedi.12732. - DOI - PubMed
    1. Cystic Fibrosis Foundation . Cystic Fibrosis Foundation Patient Registry 2018 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; c2019. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-...